Official Title: “Melatonin Levels in Sleep-Disordered Smith-Magenis Syndrome: a Pilot Study”

The goal of this pilot project is to determine whether melatonin levels are disordered in patients with Smith-Magenis Syndrome (SMS) and whether melatonin treatment can correct abnormal circadian rhythms in SMS patients. In addition, the study investigates the effects of bright light in an elderly control population that exhibits low melatonin secretion.

Study Type: Interventional

Study Design: Diagnostic, Non-Randomized, Single Blind (Subject), Parallel Assignment

Study Primary Completion Date: March 2009

Participation involves 5 stages for SMS patients. First, Subjects will complete 4 sessions of 25-hour salivary or plasma sampling, with the last sampling occurring in front of a bright light box. Second, subjects will enroll in the melatonin treatment phase, involving a daily dose (up to 3 mg) for up to one year, with frequent (every 2-4 weeks) of 25-hour salivary or plasma sampling. During this stage, the subject and/or caregiver may also be asked to wear an activity wrist monitor, complete a daily sleep diary and behavioral questionnaires. Third, the subject may be asked to complete up to 3 25-hour sampling periods and take a melatonin pill on the same day to test how their body metabolizes the hormone, melatonin. The fourth stage is for subjects who are found to have an abnormal body rhythm. Subjects will complete a 25-hour plasma sampling period under bedrest to test for a hormone, Cortisol. The fifth stage is an optional 12-hour sleep analysis (polysomnography) to test for sleep disorders.

Control participants will complete an abbreviated protocol of the 3 baseline 25-hour sampling periods and 1 involving bright light exposure.

Intervention(s) in this Clinical Trial

• Dietary Supplement: Melatonin
  • up to 3 mg, daily, for up to 1 year
• Device: Enviro-light artificial light box
  • Subjects will sit in front of an artificial, fluorescent light box (10,000 lux) while completing 25-hours of hourly plasma samples. The light lux level will be well below that identified as safe by the FDA.

Arms, Groups and Cohorts in this Clinical Trial

• Active Comparator: 2
  • Subjects will sit in front of a fluorescent bright light box while completing plasma samples to test for melatonin suppression in blood. This will be completed by both the SMS patient group and the control group of elderly individuals.
• Experimental: 1
  • Subjects will take up to 3 mg of melatonin daily and will complete frequent (every 2-4 weeks) of saliva and/or plasma sampling to test for a change in the timing of the body clock in response to the melatonin.

Primary Measures

• Circadian Phase Marker, as measured by the melatonin levels in serial salivary and/or plasma samples
  • Time Frame: every 2-4 weeks throughout the entire study
    Safety Issue?: No

Secondary Measures

• Polysomnography sleep disorder assessment
  • Time Frame: 1 optional, 12-hour assessment towards the end of the study
    Safety Issue?: No
• Wrist actigraph activity levels as a secondary indicator of circadian phase
  • Time Frame: every 2-4 weeks throughout the entire study along with every Circadian Phase Marker assessment
    Safety Issue?: No

Inclusion Criteria:

• Control participants:
• 30 individuals: ages 55-85,
• healthy without significant active medical problems.
• SMS patients:
• 20 individuals: ages 3-50,
• with a clinical diagnosis of Smith-Magenis Syndrome by a qualified Medical
• Geneticist, confirmed by cytogenetic analysis documenting deletion of chromosome band 17p11.2.

Exclusion Criteria:

• Control participants:
• A current Axis I psychiatric or substance abuse disorder according to the DSM-IV Manual, abnormal heart, liver or kidney function, diagnoses of neurodegenerative or cerebrovascular disease (Alzheimer's disease, Parkinson's disease, stroke, etc.),
• cognitive impairment (Mini-Mental State Score < 23) but without a formal diagnosis of dementia,
• active symptoms of depression (Geriatric Depression Scale: 30 pt. version > 10),
• current diagnosis of cataracts,
• macular degeneration or retinopathy based on eye exam by an optometrist or ophthalmologist within the past year.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 3 Years

Maximum Age for this Clinical Trial: 85 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers

Lead Sponsor: Oregon Health and Science University

Overall Clinical Trial Officials and Contacts

Eilis Boudreau, MD Principal Investigator Oregon Health and Science University  

Information obtained from ClinicalTrials.gov on July 02, 2009

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00691574

Study ID Number: eIRB 0668

ClinicalTrials.gov Identifier: NCT00691574

Health Authority: United States: Food and Drug Administration